FrancophonIA/ELRC3.0 huggingface dataset:
English: However, in order to make the HALAGON treatment easier, a simplified dosage scheme is proposed:
Croatian: Međutim, kako bi liječenje HALAGON-om bilo lakše, predlaže se pojednostavljena shema doziranja:
English: The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this product.
Croatian: Pomoćne tvari navedene u dijelu 6.1 SPC su ili dozvoljene tvari za koje je u tablici 1 Dodatka Uredbi Komisije (EU) br. 37/2010 navedeno da određivanje MRL-a nije nužno, ili se smatra da se na njih ne primjenjuju odredbe Uredbe (EZ) br. 470/2009 kada se primjenjuju kao u ovom proizvodu.
English: Wear protective gloves while handling the product.
Croatian: Nosite zaštitne rukavice prilikom rukovanja proizvodom.
English: In case of skin and eye contact wash the exposed area thoroughly with clean water.
Croatian: U slučaju dodira s kožom i očima isperite izloženo područje temeljito čistom vodom.
English: 1) Screw the metering pump on the bottle.
Croatian: 1) Navijte mjernu pumpicu na bocu.
English: Not for use in animals from which milk is produced for human consumption
Croatian: Nije za primjenu u životinja koje se uzgajaju za proizvodnju mlijeka za konzumaciju
English: The concentrations to inhibit 50% and 90% of the parasites, in an in vitro test system, are IC50 < 0.1 μg/ml and IC90 of 4.5
Croatian: Koncentracije za inhibiciju od 50 % odnosno 90 % parazita, u sustavu testiranja in vitro, iznose IC50 <0,1 µg/ml odnosno IC90 od 4,5 µg/ml.
English: Unchanged halofuginone is the major component in the tissues.
Croatian: Nepromijenjeni halofuginon glavni je sastojak u tkivima.
English: Once the first calf has been treated, all the forthcoming new-born calves must be systematically treated as long as the risk for diarrhoea due to C. parvum persists.
Croatian: Nakon što je prva telad tretirana i sva buduća novorođena telad mora biti sustavno tretirana sve dok postoji rizik od proljeva zbog postojeće infekcije s C. parvum.
English: Tartrazine (E102)
Croatian: Tartrazin (E102)
English: Halofuginone lactate is a salt whose antiprotozoal properties and efficacy against Cryptosporidium parvum have been demonstrated both in in vitro conditions and in artificial and natural infections.
Croatian: Halofuginon laktat je sol čija su antiprotozoalna svojstva i djelotvornost protiv Cryptosporidium parvum dokazana kako u in vitro uvjetima tako i na umjetnim i prirodnim infekcijama.
English: In very rare cases, an increase in the level of diarrhoea has been observed in treated animals.
Croatian: U vrlo rijetkim slučajevima uočeno je povećanje proljeva kod liječenih životinja.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Outer carton
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU Vanjski karton
English: The terminal elimination half-life is 11.7 hours after IV administration and 30.84 hours after single oral administration.
Croatian: Krajnje poluvrijeme eliminacije je 11,7 sati nakon intravenske primjene i 30,84 sati nakon jedne peroralne primjene.
English: Each bottle is sealed with a polypropylene cap. Each package also contains a 4 ml metering pump that consists of several components made out of high, low and linear low density polyethylene, polypropylene, stainless steel and silicone.
Croatian: Svako pakiranje sadrži i mjernu pumpicu od 4 ml koja se sastoji od nekoliko komponenti izrađenih od polietilena visoke i niske gustoće, linearnog polietilena niske gustoće, polipropilena, nehrđajućeg čelika i silikona.
English: For smaller or higher weights, a precise calculation should be performed (4 ml/20 kg).
Croatian: Za manju ili veću tjelesnu masu, treba izvršiti precizan izračun (4 ml/20 kg).
English: For oral use in calves after feeding.
Croatian: Za peroralnu uporabu u teladi nakon hranjenja.
English: DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION
Croatian: DATUM PRVOG ODOBRENJA/PRODULJENJA ODOBRENJA
English: Avoid skin, eye or mucosal contact with the product.
Croatian: Izbjegavajte kontakt proizvoda s kožom, očima ili sluznicom.
English: Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Croatian: Bilo koji neupotrebljeni veterinarsko-medicinski proizvod ili otpadni materijali dobiveni primjenom tog veterinarsko-medicinskog proizvoda moraju se odlagati u skladu s lokalnim zakonima.
English: The bioavailability of the drug in the calf following single oral administration is about 80%.
Croatian: Biodostupnost lijeka u teleta, nakon jedne peroralne primjene, je oko 80 %.
English: Antiparasitic agents/Agents acting against protozoa
Croatian: Antiparazitske tvari / tvari protiv protozoa
English: Major incompatibilities
Croatian: 6.2 Glavne inkompatibilnosti
English: Should clinical signs of overdosing occur, the treatment must be stopped immediately and the animal fed unmedicated milk or milk replacer.
Croatian: Ako se jave klinički znakovi predoziranja liječenje se mora odmah prekinuti, a životinje treba hraniti mlijekom ili mliječnom zamjenicom bez lijekova.
English: To ensure a correct dosage, an appropriate doser for administration of ‘HALAGON' is included.
Croatian: Kako bi se osigurala točna doza uključen je odgovarajući dozator za primjenu „HALAGON-a”.
English: The plasmatic concentrations of halofuginone after repeated oral administrations are comparable to the pharmacokinetic pattern after single oral treatment.
Croatian: Plazmatska koncentracija halofuginona nakon ponovljenih peroralnih primjena usporediva je s farmakokinetičkim uzorkom nakon jedne peroralne terapije.
English: For treatment of anorexic calves, the product should be administered in half a litre of an electrolyte solution.
Croatian: Za liječenje anoreksične teladi proizvod treba primijeniti s pola litre elektrolitske otopine.
English: 5) Pull the trigger of the metering pump completely for release of a dose that equals 4 ml of solution.
Croatian: 5) Povucite do kraja odponac mjerne pumpice kako bi se ispustila doza koja odgovara 4 ml otopine.
English: In new-born calves:
Croatian: U novorođene teladi:
English: Halofuginone (as lactate salt)
Croatian: Halofuginon (kao laktatna sol)
English: Cattle (newborn calves)
Croatian: Goveda (novorođena telad)
English: 4) Restrain the calf and insert the nozzle of the metering pump into the calves mouth.
Croatian: 4) Imobilizirajte tele i umetnite mlaznicu pumpe u usta teleta.
English: The apparent volume of distribution is 10 l/kg.
Croatian: Prividni obujam raspodjele iznosi 10 l/kg.
English: Administer after colostrum feeding, or after milk or milk replacer feeding only.
Croatian: Primijeniti nakon hranjenja kolostrumom, mlijekom ili mliječnim zamjenicama.
English: The active substance, halofuginone, is an antiprotozoal agent of the quinazolinone derivatives group (nitrogenous polyheterocycles).
Croatian: Djelatna tvar halofuginon je antiprotozoik iz skupine derivata kvinazolinona (dušikov poliheterociklički spoj).
English: 0.50 mg Equivalent to 0.6086 mg of halofuginone lactate
Croatian: 0,50 mg Ekvivalentno 0,6086 mg halofuginon laktata
English: Pharmacotherapeutic group: Other antiprotozoal agents, halofuginone.
Croatian: Farmakoterapijska skupina: drugi antiprozotoalne tvari, halofuginon.
English: • Prevention of diarrhoea due to diagnosed Cryptosporidium parvum infection, in farms with history of cryptosporidiosis.
Croatian: • Prevencija proljeva zbog dijagnosticirane infekcije parazitom Cryptosporidium parvum, na farmama s poviješću prethodne pojave kriptosporidioze.
English: 08503 Gurb-Vic, Barcelona Spain
Croatian: 08503 Gurb-Vic, Barcelona
English: Administration should start within 24 hours after the onset of diarrhoea.
Croatian: Primjena bi trebala započeti unutar 24 sata nakon pojave proljeva.
English: Pull twice or three times, respectively, for administration of the desired volume (8 ml for calves of 35 - 45 kg and 12 ml for calves of 45 - 60 kg, respectively).
Croatian: Povucite dva, odnosno tri puta za primjenu željene količine (8 ml za telad mase 35 - 45 kg, odnosno
English: • Reduction of diarrhoea due to diagnosed Cryptosporidium parvum infection.
Croatian: • Smanjenje proljeva zbog dijagnosticirane infekcije parazitom Cryptosporidium parvum.
English: Manufacturer responsible for batch release: Divasa-Farmavic, S.A.
Croatian: Nositelj odobrenja za proizvodnju odgovoran za puštanje serije u promet: Divasa-Farmavic, S.A.
English: Benzoic acid (E210)
Croatian: Pomoćne tvari: Benzoična kiselina (E210)
English: STATEMENT OF THE MRLs
Croatian: IZVJEŠĆE O MRL-ima
English: 0.03 mg For the full list of excipients, see section 6.1.
Croatian: Za potpuni popis pomoćnih tvari vidi dio 6.1.
English: The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
Croatian: U tiskanoj uputi o VMP-u moraju biti navedeni naziv i adresa proizvođača odgovornog za puštanje predmetne serije u promet.
English: The dosage is: 100 μg of halofuginone / kg bw / once a day for 7 consecutive days, i.e. 4 ml of HALAGON / 20 kg bw / once a day for 7 consecutive days.
Croatian: Doza je: 100 μg halofuginona / kg tjelesne mase / jednom dnevno / 7 uzastopnih dana, odnosno 4 ml HALAGON-a / 20 kg tjelesne mase / jednom dnevno / 7 uzastopnih dana.
English: EMDOKA bvba J. Lijsenstraat 16 B-2321 Hoogstraten Belgium
Croatian: EMDOKA bvba J. Lijsenstraat 16 B-2321 Hoogstraten Belgija
English: STATEMENT OF ACTIVE SUBSTANCE (S) AND OTHER INGREDIENTS
Croatian: KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNE(IH) TVARI I DRUGIH SASTOJAKA
English: It is mainly active on the free stages of the parasite (sporozoïte, merozoïte).
Croatian: Spoj ima kriptosporidiostatski učinak na Cryptosporidium parvum te je uglavnom aktivan na slobodne stadije parazita (sporozoit, merozoit).
English: EMDOKA bvba John Lijsenstraat 16 B-2321 Hoogstraten Belgium
Croatian: EMDOKA bvba John Lijsenstraat 16 B-2321 Hoogstraten Belgija
English: Shelf-life after first opening the container: 6 months.
Croatian: Rok valjanosti nakon prvog otvaranja unutarnjeg pakiranja: 6 mjeseci.
English: An appropriate device for oral administration is included.
Croatian: Uključen je odgovarajući pribor za peroralnu primjenu.
English: Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP. Shelf-life after first opening the immediate packaging: 6 months.
Croatian: Ne koristite veterinarsko-medicinski proizvod poslije isteka roka valjanosti naznačenog na etiketi poslije „EXP”.
English: Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products
Croatian: 6.6 Posebne mjere predostrožnosti za odlaganje neupotrebljenog veterinarsko-medicinskog proizvoda ili otpadnih materijala dobivenih primjenom tih proizvoda
English: Clear yellow oral solution.
Croatian: Bistra žuta peroralna otopina.
English: Shelf-life of the veterinary medicinal product as packaged for sale: 3 years Shelf-life after first opening the immediate packaging: 6 months.
Croatian: Rok valjanosti veterinarsko-medicinskih proizvoda kad je zapakiran za prodaju: 3 godine.
English: • 45 kg < calves < 60 kg: 12 ml of HALAGON once a day during 7 consecutive days
Croatian: 45 kg <telad < 60 kg: 12 ml HALAGON-a jednom dnevno, tijekom 7 uzastopnih dana.
English: Benzoic acid (E210) Lactic acid (E270) Tartrazine (E102) Water, Purified
Croatian: 6.1 Popis pomoćnih tvari Benzoična kiselina (E210) Mliječna kiselina (E270)
English: Adverse reactions (frequency and seriousness)
Croatian: 4.6 Nuspojave (učestalost i ozbiljnost)
English: Vidikovac 20, 10000 Zagreb TEL: +385 (0) 1 364 37 37
Croatian: Arnika Veterina d.o.o. Vidikovac 20, 10000 Zagreb TEL: +385 (0) 1 364 37 37
English: • 35 kg < calves ≤ 45 kg: 8 ml of HALAGON once a day during 7 consecutive days
Croatian: 35 kg < telad ≤ 45 kg: 8 ml HALAGON-a jednom dnevno, tijekom 7 uzastopnih dana,
English: Cardboard box containing one bottle (high-density polyethylene) of 290 ml, 490 ml or 980 ml of the oral solution.
Croatian: Kartonska kutija sadrži jednu bocu (polietilen visoke gustoće), koja sadrži 290 ml, 490 ml ili 980 ml peroralne otopine.
English: 2) Remove the protector cap from the nozzle.
Croatian: 2) Odstranite zaštitni čep s mlaznice.
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Bottle of 290ml, 490 ml or 980 ml
Croatian: PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKIRANJU Boca od 290 ml, 490 ml ili 980 ml
English: Cardboard box with high density polyethylene bottles of 290 ml, 490 and 980 ml.
Croatian: Kartonska kutija koja sadrži jednu bocu od polietilena visoke gustoće obujma 290 ml, 490 ml ili 980 ml.
English: CONDITIONS OF RESTRICTIONS REGARDING SUPPLY OR USE
Croatian: UVJETI ILI OGRANIČENJA U POGLEDU OPSKRBE ILI PRIMJENE
English: HALAGON 0.5 mg/ml oral solution halofuginone
Croatian: HALAGON 0,5 mg/ml peroralna otopina halofuginon
English: HALAGON 0.5 mg/ml oral solution for calves halofuginone (as lactate salt)
Croatian: HALAGON 0,5 mg/ml peroralna otopina za telad halofuginon (kao laktatna sol)
English: To ensure a correct dosage, an appropriate metering pump for administration of ‘HALAGON' is included.
Croatian: Kako bi se osigurala točna doza uključena je odgovarajuća mjerna pumpica za primjenu
English: 6) Put the protector cap back on the nozzle.
Croatian: 6) Vratite zaštitni čep na mlaznicu.
English: Oral solution.
Croatian: Za peroralnu primjenu.
English: s.r.l.
Croatian: MRL-i
English: 71 08503 Gurb-Vic, Barcelona Spain
Croatian: Sant Hipolit, Km. 71 08503 Gurb-Vic, Barcelona Španjolska
English: Amounts to be administered and administration route
Croatian: 4.9 Količine koje se primjenjuju i način primjene
English: Special precautions to be taken by the person administering the veterinary medicinal product to animals People with known hypersensitivity to the active substance or any of the excipients should administer the veterinary medicinal product with caution.
Croatian: Osobe preosjetljive na djelatnu tvar ili bilo koju od pomoćnih tvari trebaju oprezno primjenjivati veterinarsko medicinski proizvod.
English: Special precautions for use
Croatian: Posebne mjere pri čuvanju
English: Nature and composition of immediate packaging
Croatian: 6.5 Osobine i sastav unutarnjeg pakiranja
English: Bovine 10 μg/kg 25 μg/kg
Croatian: 10 µg/kg 25 µg/kg 30 µg/kg 30 µg/kg mišići masno tkivo jetra bubrezi
English: HALAGON 0.5 mg/ml oral solution for calves
Croatian: HALAGON 0,5 mg / ml peroralna otopina za telad
English: Marketing Authorisation Holder: EMDOKA bvba John Lijsenstraat 16
Croatian: Nositelj odobrenja za stavljanje u promet: EMDOKA bvba
English: Target tissues
Croatian: Peroralna otopina
English: It is taken morning and evening.
Croatian: Uzima se ujutro i uvečer.
English: Further information on Stayveer can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Više informacija o lijeku Stayveer dostupno je na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This medicine is the same as Tracleer, which is already authorised in the EU.
Croatian: Ovaj lijek isti je kao i Tracleer, koji je već odobren u EU-u.
English: What measures are being taken to ensure the safe and effective use of Stayveer?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Stayveer?
English: What is Stayveer and what is it used for?
Croatian: Što je Stayveer i za što se koristi?
English: The company that makes Tracleer has agreed that its scientific data can be used for Stayveer (‘informed consent').
Croatian: Tvrtka koja proizvodi Tracleer pristala je da se njezini znanstveni podatci koriste za lijek Stayveer (tzv. „informirani pristanak”).
English: Stayveer is available as film-coated tablets (62.5 mg and 125 mg).
Croatian: Lijek Stayveer dostupan je u obliku filmom obloženih tableta (62,5 mg i 125 mg).
English: Stayveer received a marketing authorisation valid throughout the EU on 24 June 2013.
Croatian: Lijek Stayveer dobio je odobrenje za stavljanje u promet koje je na snazi u EU-u od 24. lipnja 2013.
English: This is based on two studies in a total of 245 adults with class III or IV disease that was either primary or caused by scleroderma.
Croatian: To se temelji na dvama ispitivanjima koja su obuhvaćala ukupno 245 odraslih osoba s bolesti III. ili IV. stupnja koja je bila primarna ili uzrokovana sklerodermom.
English: In adults, the starting dose is 62.5 mg twice a day for four weeks, which is increased to the usual dose of 125 mg twice a day.
Croatian: Terapiju u odraslih osoba treba započeti s dozom od 62,5 mg dvaput dnevno tijekom četiri tjedna te zatim povećati na uobičajenu dozu od 125 mg dvaput dnevno.
English: There were too few patients with class IV disease to support the use of the medicine in this group.
Croatian: Nije bilo dovoljno bolesnika s bolesti IV. stupnja kako bi se potvrdilo korištenje lijeka u toj skupini.
English: Side effects reported with Stayveer are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Stayveer pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: In the first study, patients taking Stayveer had an average of 1.4 new digital ulcers after 16 weeks, compared with 2.7 in the patients taking placebo.
Croatian: U prvom ispitivanju bolesnici koji su uzimali Stayveer imali su prosječno 1,4 nove digitalne ulceracije nakon 16 tjedana, u usporedbi s 2,7 u bolesnika koji su uzimali placebo.
English: This medicine overview was last updated in 10-2019.
Croatian: Sažetak je posljednji put ažuriran u 10. 2019.
English: By expanding these blood vessels, pressure is reduced and symptoms are improved.
Croatian: Širenjem tih krvnih žila krvni tlak se snižava, a simptomi se ublažavaju.
English: Other information about Stayveer
Croatian: Ostale informacije o lijeku Stayveer
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Stayveer have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Stayveer nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: As for all medicines, data on the use of Stayveer are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Stayveer kontinuirano se prate.
English: Why is Stayveer authorised in the EU?
Croatian: Zašto je lijek Stayveer odobren u EU-u?
English: The second study which also looked at the effect of Stayveer on digital ulcer healing in 190 patients did not find any effect.
Croatian: U drugom ispitivanju, u kojem se promatrao i učinak lijeka Stayveer na zacjeljivanje digitalnih ulceracija u 190 bolesnika, nije utvrđen učinak.
English: • caused by scleroderma (also called systemic sclerosis, a disease where there is abnormal growth of the connective tissue that supports the skin and other organs);
Croatian: • uzrokovan sklerodermom (naziva se i sistemska skleroza, bolest u slučaju koje postoji abnormalan rast vezivnoga tkiva koje podržava kožu i ostale organe);
English: Stayveer must not be used in patients who have certain liver problems, who are pregnant or could become pregnant and who are not using reliable contraceptive methods or who are taking ciclosporin (a medicine that acts on the immune system).
Croatian: Stayveer se ne smije koristiti u bolesnika koji imaju određene probleme s jetrom, u trudnica ili žena reproduktivne dobi koje ne koriste pouzdane kontracepcijske metode ili koje uzimaju ciklosporin (lijek koji djeluje na imunosni sustav).
English: The European Medicines Agency decided that Stayveer's benefits are greater than its risks and recommended that it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Stayveer nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u EU-u.
English: What are the risks associated with Stayveer?
Croatian: Koji su rizici povezani s lijekom Stayveer?
English: However, Stayveer decreased the resistance to blood flow by 23%, indicating a widening of the blood vessels, compared with placebo after 6 months of treatment.
Croatian: Međutim, lijek Stayveer je smanjio otpor protjecanju krvi za 23 %, što ukazuje na proširenje krvnih žila, u usporedbi s placebom nakon šest mjeseci liječenja.
English: The most common side effects with Stayveer (which may affect more than 1 in 10 people) are headache, fluid retention, anaemia (low levels of haemoglobin, the protein in red blood cells that carries oxygen around the body) and abnormal results of blood tests to check the liver.
Croatian: Najčešće nuspojave lijeka Stayveer (koje se mogu javiti u više od 1 na 10 osoba) jesu glavobolja, zadržavanje tekućine, anemija (niska razina hemoglobina, bjelančevine u crvenim krvnim stanicama koje prenose kisik kroz tijelo) i abnormalni rezultati krvnih pretraga za provjeru funkcije jetre.
English: The company that makes Stayveer will provide a patient alert card to remind patients of the need for regular blood tests for liver function and to use effective contraception to avoid pregnancy.
Croatian: Tvrtka koja proizvodi lijek Stayveer osigurat će karticu s upozorenjima za bolesnike kojom se bolesnike upozorava na potrebu redovitih krvnih pretraga funkcije jetre i primjene pouzdanih kontracepcijskih sredstava radi izbjegavanja trudnoće.
English: • caused by congenital (inborn) heart defects with shunts (abnormal passageways) causing abnormal flow of blood through the heart and lungs.
Croatian: • uzrokovan kongenitalnim (urođenim) srčanim manama sa šantovima (abnormalnim prolazima) koji uzrokuju nenormalno protjecanje krvi kroz srce i pluća.
English: An overview of Stayveer and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Stayveer i zašto je odobren u EU-u
English: Stayveer is used to treat patients with class III pulmonary arterial hypertension (PAH) to improve exercise capacity (the ability to carry out physical activity) and reduce symptoms.
Croatian: Stayveer se koristi za liječenje bolesnika s plućnom arterijskom hipertenzijom (PAH) III. stupnja kako bi se poboljšao kapacitet fizičkog opterećenja (sposobnost izvođenja fizičke aktivnosti) i ublažili simptomi.
English: For more information about using Stayveer, see the package leaflet or contact your doctor or pharmacist.
Croatian: Za više informacija o primjeni lijeka Stayveer pogledajte uputu o lijeku odnosno obratite se liječniku ili ljekarniku.
English: In PAH, severe narrowing of the blood vessels in the lungs increases blood pressure and reduces the amount of blood entering the lungs.
Croatian: U slučaju PAH-a jako suženje krvnih žila u plućima povećava krvni tlak i smanjuje količinu krvi koja ulazi u pluća.
English: Similar results were seen in a study in 54 adults with class III PAH that was associated with congenital heart defects.
Croatian: Slični su rezultati zabilježeni u ispitivanju provedenom na 54 odrasle osobe s PAH-om III. stupnja koji je bio povezan s kongenitalnom srčanom manom.
English: Stayveer is given to reduce the number of new digital ulcers.
Croatian: Lijek Stayveer daje se radi smanjenja broja novih digitalnih ulceracija.
English: Stayveer contains the active substance bosentan.
Croatian: Stayveer sadrži djelatnu tvar bosentan.
English: Stayveer can also be used in adults with systemic sclerosis in whom poor blood circulation caused by the disease has led to the development of digital ulcers (sores on the fingers and toes).
Croatian: Stayveer se može koristiti i u odraslih osoba sa sistemskom sklerozom, u kojih je slaba cirkulacija uzrokovana bolešću dovela do stvaranja digitalnih ulceracija (rana na prstima ruku i nogu).